Baseline Factors Linked With Outcome in BRAF-Mutant Melanoma
Aug 17, 2018
Baseline levels of lactate dehydrogenase are significantly associated with progression-free survival outcomes in patients with BRAF V600–mutated metastatic melanoma.
Recent Content
Several Genetic Variants Associated With Increased TNBC Risk
Aug 16, 2018
A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.
Magnetic Drug Targeting May Help Reach CNS Tumors
Aug 16, 2018
Targeted delivery of nanoparticles may reduce systemic and CNS toxicity in spinal cord tumors.
Does Radioactive Iodine Post Reoperation Improve Thyroid Cancer Outcomes?
Aug 16, 2018
A study shows that receipt of radioactive iodine after reoperation may not be associated with improved outcomes.
Locoregional Recurrence Rates Vary Based on Several Factors in Bladder Cancer
Aug 16, 2018
A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice—PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
Aug 15, 2018
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.
Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points
Aug 15, 2018
The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
Obese Breast Cancer Patients and Survivors: Management Considerations
Aug 15, 2018
This article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship.
POINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
Aug 15, 2018
Balancing the goal of obtaining a durable remission and that of avoiding a negative impact on quality of life argues against the routine use of chemotherapy in follicular lymphoma.
COUNTERPOINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
Aug 15, 2018
It is clear that chemoimmunotherapy has redefined the history of follicular lymphoma, producing survival rates measured in decades.
